Five-year survival outcomes in NSCLC patients with concurrent GERD on proton pump inhibitors receiving pembrolizumab or nivolumab: A global study.

Authors: Yohannes Haile, Allen Seylani, Assal Sadighian

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20611

Source: Full article

---

Abstract

e20611